Stimuli-Responsive and Highly Penetrable Nanoparticles as a Multifunctional Nanoplatform for Boosting Nonsmall Cell Lung Cancer siRNA Therapy
Source abstract
Abstract
In cancer therapy, it is acknowledged that large-size nanoparticles stay in the circulation system for a long time, but their permeability to tumor tissues is poor. To address the conflicting need for prolonging circulation time and favorable tumor tissue penetration ability, a charge conversional multifunctional nanoplatform was strategically designed to improve the efficacy of small interfering RNA (siRNA) therapy against nonsmall cell lung cancer (NSCLC). The development of nanodrug delivery systems (NDDSs) was constructed by loading siRNA on polyamidoamine (PAMAM) dendrimers to build small-sized PAM/siRNA via electrostatic interaction and then capped with a pH-triggered copolymer poly(ethylene glycol) methyl ether (mPEG)-poly-l-lysine (PLL)-2,3-dimethylmaleic anhydride (DMA) (shorted as PLM) under physiological conditions. While in the tumor microenvironment, the acidic reaction of the PLM copolymer changes from negative charge to positive charge due to the cleavable amide bond between mPEG-PLL and DMA, leading to large-size nanoparticles (NPs) with a negative charge that turns into a positive charge and small NPs with a high tumor-penetrating ability. All of the in vitro and in vivo studies validated that PLM/PAM/siRNA NPs possess desirable features including excellent biocompatibility, a prolonged circulation time, significant pH sensitivity, high tumor tissue penetration ability, and sufficient endo-/lysosomal escape. Taken together, all results suggest tremendous potential of the gene therapy based on the stimuli-sensitive PLM/PAM/siRNA NPs, providing a profound application prospective treatment strategy in cancer gene therapy.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Advanced biosensing and bioanalysis techniques · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Pharmacy, Shenyang Pharmaceutical University, No. 103 Wenhua Road, Shenyang, Liaoning Province 110016, P. R. China
Hongqi Hostital, Mudanjiang Medical University, No. 5 Tongxiang Road, Mudanjiang, Heilongjiang Province 157011, P. R. China
Funding
National Natural Science Foundation of China
References (46)
Show source-provided references
1. 10.1038/s41573-019-0020-910.1038/s41573-019-0020-9 ↗
2. 10.1038/nm.379310.1038/nm.3793 ↗
3. 10.2147/IJN.S18011910.2147/IJN.S180119 ↗
4. 10.1038/ncomms1182210.1038/ncomms11822 ↗
5. 10.1038/nrc.2016.10810.1038/nrc.2016.108 ↗
6. 10.1038/s41467-019-11718-410.1038/s41467-019-11718-4 ↗
7. 10.1016/j.biomaterials.2018.01.04210.1016/j.biomaterials.2018.01.042 ↗
8. 10.1021/nn103130q10.1021/nn103130q ↗
9. 10.1021/nl500214e10.1021/nl500214e ↗
10. 10.1021/acsnano.6b0719510.1021/acsnano.6b07195 ↗
11. 10.1002/anie.20160127310.1002/anie.201601273 ↗
12. 10.1016/j.nantod.2020.10092410.1016/j.nantod.2020.100924 ↗
13. 10.1016/j.actbio.2019.10.00610.1016/j.actbio.2019.10.006 ↗
14. 10.1016/j.jconrel.2006.04.01410.1016/j.jconrel.2006.04.014 ↗
15. 10.1021/cr300213b10.1021/cr300213b ↗
16. 10.1016/j.biomaterials.2016.06.00510.1016/j.biomaterials.2016.06.005 ↗
17. 10.1016/j.jconrel.2018.08.00210.1016/j.jconrel.2018.08.002 ↗
18. 10.1016/j.colsurfb.2017.11.00610.1016/j.colsurfb.2017.11.006 ↗
19. 10.1016/j.jconrel.2019.09.00410.1016/j.jconrel.2019.09.004 ↗
20. 10.1016/j.addr.2018.05.00810.1016/j.addr.2018.05.008 ↗
21. 10.1016/j.biomaterials.2017.10.02410.1016/j.biomaterials.2017.10.024 ↗
22. 10.1016/j.biomaterials.2020.11990210.1016/j.biomaterials.2020.119902 ↗
23. 10.1021/acs.nanolett.7b0002110.1021/acs.nanolett.7b00021 ↗
24. 10.1002/smll.20200417210.1002/smll.202004172 ↗
25. 10.1021/nn500299p10.1021/nn500299p ↗
26. 10.1016/j.nano.2015.04.01510.1016/j.nano.2015.04.015 ↗
27. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
28. 10.1021/acs.biomac.7b0006810.1021/acs.biomac.7b00068 ↗
29. 10.1021/acsnano.5b0201710.1021/acsnano.5b02017 ↗
30. 10.1021/acsami.8b2158010.1021/acsami.8b21580 ↗
31. 10.1016/j.jconrel.2015.12.00610.1016/j.jconrel.2015.12.006 ↗
32. 10.1016/j.actbio.2015.11.03710.1016/j.actbio.2015.11.037 ↗
33. 10.1039/C9BM00812H10.1039/C9BM00812H ↗
34. 10.1038/natrevmats.2017.2010.1038/natrevmats.2017.20 ↗
35. 10.1002/smll.20180256510.1002/smll.201802565 ↗
36. 10.1021/acs.nanolett.9b0468310.1021/acs.nanolett.9b04683 ↗
37. 10.1016/j.canlet.2018.08.00710.1016/j.canlet.2018.08.007 ↗
38. 10.1021/acs.nanolett.9b0166010.1021/acs.nanolett.9b01660 ↗
39. 10.1002/anie.20201117410.1002/anie.202011174 ↗
40. 10.1016/j.biomaterials.2020.12000810.1016/j.biomaterials.2020.120008 ↗
41. 10.1039/C9TB02764E10.1039/C9TB02764E ↗
42. 10.1016/j.biomaterials.2021.12071110.1016/j.biomaterials.2021.120711 ↗
43. 10.1016/j.nantod.2020.10105810.1016/j.nantod.2020.101058 ↗
44. 10.1021/acsnano.0c0641510.1021/acsnano.0c06415 ↗
45. 10.1016/j.apsb.2019.02.01010.1016/j.apsb.2019.02.010 ↗
46. 10.1016/j.biomaterials.2020.12057410.1016/j.biomaterials.2020.120574 ↗